title: Estrogens reduce plasma histidine-rich glycoprotein (HRG) levels in a dose-dependent way.
abstract: Plasma levels of histidine-rich glycoprotein (HRG) were investigated in three groups of women receiving a different dose of estrogens. First, the effect of low-dose estrogen was studied in a group of 83 postmenopausal women who were treated with 0.625 mg conjugated estrogens (CE). No significant change from baseline levels was found at the end of cycle 3 and cycle 13. Secondly, in 15 mothers and 23 daughters using oral contraceptives (OC) containing 30-50 micrograms ethinyl estradiol (EE) daily the mean HRG level was 14% and 24% lower than in a group of 144 mothers and 134 daughters not taking oral contraceptives, respectively (p < 0.05). Finally, in 11 excessively tall prepuberal girls who received 300 micrograms EE daily to reduce their final height the mean plasma HRG levels were decreased by 68% (p < 0.005). The effect of progestogens administered during low-dose and high-dose estrogen therapy appeared to be minor. The results from these three studies indicate that estrogens reduce plasma HRG levels in a dose-dependent way.
authors.affiliation: Gaubius Laboratory, TNO-PG, Leiden, The Netherlands.
authors.forename: B C
authors.initials: BC
authors.lastname: Hennis
authors.forename: D I
authors.initials: DI
authors.lastname: Boomsma
authors.forename: K
authors.initials: K
authors.lastname: Fijnvandraat
authors.forename: J A
authors.initials: JA
authors.lastname: Gevers Leuven
authors.forename: M
authors.initials: M
authors.lastname: Peters
authors.forename: C
authors.initials: C
authors.lastname: Kluft
mesh_terms: D000293:Adolescent; D000367:Age Factors; D000368:Aged; D001827:Body Height / Q000187:drug effects; D002648:Child; D003278:Contraceptives, Oral, Hormonal / Q000009:adverse effects / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004966:Estrogens, Conjugated (USP) / Q000009:adverse effects / Q000494:pharmacology*; D004997:Ethinyl Estradiol / Q000009:adverse effects / Q000494:pharmacology*; D005260:Female; D005877:Gigantism / Q000517:prevention & control; D006801:Humans; D008524:Medrogestone / Q000494:pharmacology*; D017258:Medroxyprogesterone Acetate / Q000494:pharmacology*; D008875:Middle Aged; D017698:Postmenopause; D011506:Proteins / Q000032:analysis*; D012306:Risk; D013923:Thromboembolism / Q000097:blood / Q000139:chemically induced / Q000453:epidemiology; D000099053:Histidine-Rich Glycoprotein
chemical_list: D003278:Contraceptives, Oral, Hormonal; D004966:Estrogens, Conjugated (USP); D011506:Proteins; D000099053:Histidine-Rich Glycoprotein; D008524:Medrogestone; D004997:Ethinyl Estradiol; D017258:Medroxyprogesterone Acetate